ArticleContemporary oncology (Poznan, Poland)2024
Prognostic value of human papilloma virus (HPV) status and programmed cell death ligand 1 (PD-L1) status in oral tongue cancer.
Article in Contemporary oncology (Poznan, Poland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Despite advances in diagnostics and therapy, the 5-year mortality rate of oral squamous cell cancer (OSCC) remains at about 50%. Prognostic molecular biomarkers are not yet approved for clinical application, mainly due to conflicting results. The aim of our study was to determine the programmed cell death ligand 1 (PD-L1) status in oral tongue squamous cell carcinoma and their influence on patients' outcomes. Material and methods: Primary tumours were collected from 44 patients who underwent tumour surgical resection for primary OSCC from 2018 to 2022. Additionally demographic and clinical data were gathered. Results: Final analysis included patients with a mean age of 61 years (range 26-90), mostly males ( Conclusions: Patients with higher PD-L1 status in our study had better survival, which is contradictory to most of the published data. The reason for this may be the different detection method, and the examination of PD-L1 through mRNA is considered precise and repetitive. Studies with higher numbers of patients are needed to validate our conclusions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.